2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall StreetThe Motley Fool • 03/26/24
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?The Motley Fool • 03/07/24
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street AnalystThe Motley Fool • 03/06/24
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung CancerGlobeNewsWire • 03/04/24
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?The Motley Fool • 02/29/24
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/28/24
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 02/28/24
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall StreetThe Motley Fool • 02/26/24